These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 31713736)

  • 1. Treatment of Excessive Daytime Sleepiness in Patients with Narcolepsy.
    Pérez-Carbonell L
    Curr Treat Options Neurol; 2019 Nov; 21(11):57. PubMed ID: 31713736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications.
    Thorpy MJ; Bogan RK
    Sleep Med; 2020 Apr; 68():97-109. PubMed ID: 32032921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recently Approved and Upcoming Treatments for Narcolepsy.
    Thorpy MJ
    CNS Drugs; 2020 Jan; 34(1):9-27. PubMed ID: 31953791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives.
    Abad VC
    Nat Sci Sleep; 2021; 13():75-91. PubMed ID: 33531850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
    Sarfraz N; Okuampa D; Hansen H; Alvarez M; Cornett EM; Kakazu J; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(3):34222. PubMed ID: 35774905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in the management of narcolepsy.
    Abad VC; Guilleminault C
    Nat Sci Sleep; 2017; 9():39-57. PubMed ID: 28424564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy.
    Thorpy MJ; Hyman D; Parks GS; Chen A; Foley C; Baldys B; Ito D; Singh H
    Clin Ther; 2022 Oct; 44(10):1356-1369. PubMed ID: 36171171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in treatment for narcolepsy.
    Barateau L; Dauvilliers Y
    Ther Adv Neurol Disord; 2019; 12():1756286419875622. PubMed ID: 31632459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
    Krief S; Berrebi-Bertrand I; Nagmar I; Giret M; Belliard S; Perrin D; Uguen M; Robert P; Lecomte JM; Schwartz JC; Finance O; Ligneau X
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00855. PubMed ID: 34423920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness.
    Inocente C; Arnulf I; Bastuji H; Thibault-Stoll A; Raoux A; Reimão R; Lin JS; Franco P
    Clin Neuropharmacol; 2012; 35(2):55-60. PubMed ID: 22356925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current and emerging options for the drug treatment of narcolepsy.
    De la Herrán-Arita AK; García-García F
    Drugs; 2013 Nov; 73(16):1771-81. PubMed ID: 24122734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic Management of Excessive Daytime Sleepiness.
    Ono T; Takenoshita S; Nishino S
    Sleep Med Clin; 2022 Sep; 17(3):485-503. PubMed ID: 36150809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advances in treatment of narcolepsy].
    Xu Q; Lou G; Wang T; Zhang L
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 49(4):419-424. PubMed ID: 32985153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.
    Szabo ST; Thorpy MJ; Mayer G; Peever JH; Kilduff TS
    Sleep Med Rev; 2019 Feb; 43():23-36. PubMed ID: 30503715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Narcolepsy.
    Barateau L; Lopez R; Dauvilliers Y
    Curr Treat Options Neurol; 2016 Oct; 18(10):43. PubMed ID: 27549768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on Persistent Excessive Daytime Sleepiness in OSA.
    Javaheri S; Javaheri S
    Chest; 2020 Aug; 158(2):776-786. PubMed ID: 32147246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological management of narcolepsy with and without cataplexy.
    Kallweit U; Bassetti CL
    Expert Opin Pharmacother; 2017 Jun; 18(8):809-817. PubMed ID: 28443381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on therapy for narcolepsy.
    Thorpy MJ
    Curr Treat Options Neurol; 2015 May; 17(5):347. PubMed ID: 25854650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central Disorders of Hypersomnolence: Focus on the Narcolepsies and Idiopathic Hypersomnia.
    Khan Z; Trotti LM
    Chest; 2015 Jul; 148(1):262-273. PubMed ID: 26149554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging treatments for narcolepsy and its related disorders.
    Nishino S; Okuro M
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):139-58. PubMed ID: 20166851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.